Compare Citigroup Inc. (C) vs Novo Nordisk A/S (NVO) Price & Performance

Citigroup Inc.Trade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs Novo Nordisk A/S — how do they compare? Citigroup Inc. trades at $134.33 (market cap $227.30B), while Novo Nordisk A/S trades at $49.07 (market cap $214.94B). The key difference: Citigroup Inc. and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.

	C	NVO
Market Cap	$227.30B	$214.94B
Sector	Financials	Health
52-Week High	$145.67	$71.70
52-Week Low	$90.02	$35.29
Dividend Yield	1.8%	3.67%
Enterprise Value	—	$233.91B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.

The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.

Novo Nordisk A/S

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Citigroup beats Q2 earnings estimates with $24.77B revenue and $3.15 EPS, driven by strong trading and banking.Tony Dante · 16 hours agoBullish Citigroup posts strong Q2 with 14% revenue growth, 61% EPS jump, and boosts dividends by 12%.Seeking Alpha · 20 hours agoBullish Citigroup beats Q2 revenue estimates on strong trading and investment banking resultsProactive Investors · 1 day agoBullish View details →

NVO

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trendsCustom Market Insights · 1 day agoBullish Vivani develops semaglutide implant to improve long-term weight loss adherence for GLP-1 usersCNBC · 4 days agoBullish View details →

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.